This scientific agreement (the „agreement“) will be concluded on February 28, 2020 between Moleculin Biotech, Inc. (the „company“) and Waldemar Priebe, PhD (the „scientific advisor“). CET ACCORD (the „agreement“) of May 1, 2006 („Date of effect“) is concluded by and between Medgenics, Inc. at 8000 Towers Crescent Drive, Suite 1300, Vienna, VA, 22182. U.S. „Dr. Lopez-Talavera has a reputation for developing disruptive technologies that we believe are crucial for compounds like BXT-25 of bioxytran. It is rare to have such a qualified candidate in a development company like bioxytran, and we consider this to be a confirmation of our plans for BXT-25. BOSTON (MASSACHUSETTS) May 6, 2019 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTC: BIXT), a biotechnology company that is developing a pipeline of anti-necrosis drugs to treat hypoxia by providing a small molecule carrying oxygen to the brains of stroke victims, announced today that it has retained Juan Carlos Lopez-Talavera, MD, PhD, to join Bioxytran`s scientific committee to manage the company`s licensing process.
BXT-25. This amendment to the Scientific Advisory Board („Amendment“) agreement will be completed on July 21, 2011 („Execution Date“) by and between Dr. Joe M. McCord, Ph.D., and LifeVantage Corporation, a Colorado company (the „company“). THIS NUMBER OF AMENDMENT NO 1 ZU WISSENSCHAFTLICHEN ADVISORY BOARD AGREEMENT (die „nderung“) dates from September 21, 2016 between Enumeral Biomedical Holdings, Inc., a Delaware company (with its subsidiaries, the „Company“), and Barry Buckland, Ph.D. (the „consultant“). This amendment amends the fact that a specific agreement on the Scientific Advisory Committee, dated 14 September 2014, was concluded by and between the company and the advisor (the „DEE Agreement“). The wholesale words that are used here, but which are not otherwise defined, must have the meanings attributed to these terms in the SAB agreement. .
. . „During my professional career, I have always started working with new mechanisms,“ said Dr. Lopez-Talavera. „Bioxytran is highly likely because tissue oxygenation is a truly unmet medical need and provides an unworkable opportunity to target both stroke and have lasting symptoms of Acute Respiratory Distress Syndrome (ARDS). BXT-25 has the unique ability to provide oxygen through a small molecule that can extend the golden hour in stroke victims and possibly extend the golden hour in ARDS victims. I am honoured to be part of this team and look forward to advancing science and creating partnerships or joint ventures that will develop this area of research. CET ACCORD (the „agreement“) is concluded on December 24, 2013 (effective date) between Lixte Biotechnology Holdings, Inc., 248 Route 25A No.